Edition:
United States

Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

1.95USD
16 Feb 2018
Change (% chg)

$-0.07 (-3.47%)
Prev Close
$2.02
Open
$2.04
Day's High
$2.04
Day's Low
$1.95
Volume
1,226
Avg. Vol
5,763
52-wk High
$6.80
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Oragenics Inc Announces Reverse Stock Split At Ratio Of 1 For 10
Monday, 8 Jan 2018 07:15am EST 

Jan 8 (Reuters) - Oragenics Inc ::ORAGENICS, INC. ANNOUNCES REVERSE STOCK SPLIT.ORAGENICS - ANNOUNCED REVERSE SPLIT OF COMMON STOCK AT A RATIO OF 1 FOR 10, EFFECTIVE JAN 19.  Full Article

Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis
Thursday, 31 Aug 2017 07:30am EDT 

Aug 31 (Reuters) - Oragenics Inc :Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis.Oragenics Inc - Completion and full results of phase 2 trial expected by end of 2018​.Oragenics Inc - Expect to report preliminary data on initial 20 enrolled patients by end of 2017.  Full Article

Oragenics announces $3 mln preferred stock private placement and $2.4 mln loan
Thursday, 11 May 2017 07:45am EDT 

May 11 (Reuters) - Oragenics Inc :Oragenics announces $3.0 million preferred stock private placement and $2.4 million loan.Oragenics inc - to sell up to $3.0 million of series a convertible preferred stock at a price of $0.25 per share.Oragenics inc - concurrently with preferred stock financing, company also entered into a note purchase agreement with intrexon corporation.Oragenics inc - intrexon note matures in two years and has a simple interest rate of 12% per annum.Oragenics inc - proceeds from intrexon note will be used to fund company's ag013 research and clinical trials.Oragenics inc - proceeds from stock offering, loan to continue advancing biotherapeutic candidate ag013 toward clinic for treatment of oral mucositis.Oragenics inc - issued $2.4 million unsecured non-convertible promissory note to intrexon & amended first milestone in its oral mucositis ecc agreement with intrexon.  Full Article

Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis
Monday, 21 Nov 2016 03:33pm EST 

Oragenics Inc : U.S. FDA grants fast track designation for the development of Oragenics' AG013 for oral mucositis .Oragenics - expects to file an Investigational New Drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017.  Full Article

Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017
Monday, 21 Nov 2016 07:45am EST 

Oragenics Inc : Oragenics - expects to file an investigational new drug (ind) update and initiate a phase 2 study with ag013 in united states and europe in early 2017 . Oragenics -a phase 1b clinical trial with ag013 in 25 head,neck cancer patients at high risk for om demonstrated that ag013 was safe and well tolerated .U.S. FDA grants fast track designation for the development of oragenics' ag013 for oral mucositis.  Full Article

Oragenics receives supportive FDA feedback for initiating a phase 2 study protocol for Oral Mucositis Treatment
Tuesday, 30 Aug 2016 08:15am EDT 

Oragenics Inc : Oragenics receives supportive FDA feedback for initiating a phase 2 study protocol for Oral Mucositis Treatment . Expects to file Investigational New Drug (ind) update in late 2016 . Oragenics Inc says to initiate study with ag013 in united states and europe during early 2017 .Applications for biologic license application exclusivity and fast track designation with FDA will be filed in coming months.  Full Article

Oragenics Inc files for stock shelf of upto $30 mln
Thursday, 25 Aug 2016 05:24pm EDT 

Oragenics Inc :Files for stock shelf of upto $30 million - SEC filing.  Full Article

Oragenics Inc says Alan Joslyn to be new president and CEO
Monday, 6 Jun 2016 04:51pm EDT 

Oragenics Inc : Oragenics announces new president, chief executive officer and member of the board of directors .Oragenics Inc says Alan Joslyn will be company's new president and chief executive officer.  Full Article

BRIEF-Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

* Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

No consensus analysis data available.